Envision Healthcare Gets a Buy from Canaccord GenuityBy Ryan Adsit
According to TipRanks.com, Close is a 5-star analyst with an average return of 19.4% and a 57.3% success rate. Close covers the Technology sector, focusing on stocks such as Castlight Health, Evolent Health, and Athenahealth.
Currently, the analyst consensus on Envision Healthcare is Strong Buy and the average price target is $80.25, representing a 36.8% upside.
In a report issued on April 6, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $80 price target.
Based on Envision Healthcare’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $1.39 billion and GAAP net loss of $136 million. In comparison, last year the company earned revenue of $725 million and had a net profit of $30.86 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Envision Healthcare Corp. provides healthcare services, including physician-led services, ambulatory surgery center management, post-acute care and medical transportation. It owns and operates surgery centers and surgical hospital with medical specialties ranging from gastroenterology to ophthalmology and orthopedics. Envision Healthcare operates ambulatory surgery centers; and provides a suite of medical transportation solutions and deliver prevention, intervention and post-acute care services. The company also offers outsourced physician services in the following specialties: emergency medicine, anesthesiology, hospital medicine, women’s and children’s services, radiology and surgery. Its brands include American Medical Response, EmCare and Evolution Health. The company was founded in December 2016 and is headquartered in Nashville, TN.